Abstract Background Checkpoint inhibitors (CPIs) are widely used in cancer treatment, with
transformative impacts on survival. They nonetheless carry a significant risk of toxicity in the …

Immune checkpoint inhibitors (ICPis) are emerging as the new corner stone of cancer
treatment due to their ability to produce durable responses in patients with various cancers …

Despite encouraging results with immune checkpoint inhibition (ICI), a large fraction of
cancer patients still does not achieve clinical benefit. Finding predictive markers in the …

Immune checkpoint inhibitors have demonstrated significant survival benefits in treating
many types of cancers. However, their immune-related adverse events (irAEs) have not …

Immune checkpoint inhibitors (ICIs) are pharmaceutical agents capable of disrupting
immune checkpoint signaling, leading to T-cell activation and a robust anti-tumor response …

Immune checkpoint inhibitors (ICIs) have revolutionised oncology and are now standard-of-
care for the treatment of a wide variety of solid neoplasms. However, tumour responses …

Immune checkpoint inhibitors (ICI) have revolutionized the treatment landscape of advanced
malignancies, but come with a diverse spectrum of immune-related adverse events (irAEs) …

Immune checkpoint inhibitors (ICI) have provided new hope for cancer patients, and in
particular for patients with tumors that are immunologically active and classified as hot …

Therapeutic antibodies designed to target immune checkpoint proteins such as PD-1, PD-
L1, and CTLA-4 have been applied in the treatment of various tumor types, including small …

Immune checkpoint inhibitors (ICI) represented a major breakthrough for the treatment of
human cancer. Most patients, however, do not benefit from treatment with these agents, thus …